Heimberger T S, Duma R J
Department of Medicine, Medical College of Virginia, Richmond.
Infect Dis Clin North Am. 1989 Jun;3(2):221-45.
Prosthetic valve endocarditis may be considered present when two fo the following criteria are met: (1) two or more blood cultures are positive with the same organism in the absence of extracardiac infections, (2) evidence of bacterial endocarditis by histology or cultures is obtained from surgical or autopsy specimens, and/or (3) a clinical picture compatible with endocarditis (fever, new or changing regurgitant murmur, splenomegaly, hematuria, or evidence of peripheral emboli) is present. The overall incidence of PVE ranges from 0.98 to 4.4 per cent. Early and late PVE (that is endocarditis developing less than 60 and 60 or more days following valve implantation, respectively) accounts for 18 to 36 per cent and 64 to 82 per cent of infections, respectively. The overall mortality is 53 per cent and is higher in patients with early versus late PVE. Coagulase-negative staphylococci are responsible for a higher percentage of early (43 per cent) than late (28 per cent) infections. Streptococci are more common in late (27 per cent) than in early (3 per cent) PVE, while diphtheroids are most common in early PVE. The diagnosis of PVE may be difficult to establish, especially in patients with postoperative bacteremias who have other potential sources of extracardiac infections. Antimicrobial therapy is generally based on the susceptibility of the offending pathogen. With respect to the use of synergistic combinations, results are controversial, and most available data are derived from patients with native-valve endocarditis. Surgery remains an important aspect of treatment, and the mortality among patients who undergo early surgical intervention, particularly if their illness is complicated, is less than in those who are treated only with antibiotics. Indications for surgery include: (1) moderate-severe refractory congestive heart failure, (2) persistent bacteremia or fungemia, (3) multiple emboli, (4) myocardial abscesses, (5) relapsing PVE, and possibly (6) patients with clinical evidence of PVE and negative blood cultures and persistent fever despite 1 week or more of appropriate antibiotics. Pacemaker infections occur in less than 6 per cent of patients who undergo pacemaker insertion. These infections generally result from wound contamination at the time of surgery, and 75 per cent of infections are due to staphylococci. Staphylococcus aureus causes most infections occurring within 2 weeks after surgery, while S. epidermidis causes most later infections. The need to remove infected pacemakers is controversial.
(1)在无心脏外感染的情况下,两份或更多份血培养出同一病原体阳性;(2)通过组织学或培养从手术或尸检标本中获得细菌性心内膜炎的证据,和/或(3)存在与心内膜炎相符的临床表现(发热、新出现或变化的反流性杂音、脾肿大、血尿或外周栓塞证据)。人工瓣膜心内膜炎的总体发病率为0.98%至4.4%。早期和晚期人工瓣膜心内膜炎(即分别在瓣膜植入后不到60天和60天或更长时间发生的心内膜炎)分别占感染的18%至36%和64%至82%。总体死亡率为53%,早期人工瓣膜心内膜炎患者的死亡率高于晚期患者。凝固酶阴性葡萄球菌导致早期感染(43%)的比例高于晚期感染(28%)。链球菌在晚期人工瓣膜心内膜炎(27%)中比在早期(3%)中更常见,而类白喉杆菌在早期人工瓣膜心内膜炎中最常见。人工瓣膜心内膜炎的诊断可能难以确立,尤其是在有术后菌血症且有其他心脏外感染潜在来源的患者中。抗菌治疗一般基于致病病原体的药敏情况。关于使用协同联合用药,结果存在争议,且大多数现有数据来自自体瓣膜心内膜炎患者。手术仍然是治疗的一个重要方面,早期接受手术干预的患者(尤其是病情复杂者)的死亡率低于仅接受抗生素治疗的患者。手术指征包括:(1)中重度难治性充血性心力衰竭;(2)持续性菌血症或真菌血症;(3)多次栓塞;(4)心肌脓肿;(5)复发性人工瓣膜心内膜炎,可能还有(6)有临床证据支持人工瓣膜心内膜炎但血培养阴性且在使用适当抗生素1周或更长时间后仍持续发热的患者。起搏器感染发生在接受起搏器植入的患者中不到6%。这些感染通常源于手术时伤口污染,75%的感染由葡萄球菌引起。金黄色葡萄球菌导致大多数术后2周内发生的感染,而表皮葡萄球菌导致大多数后期感染。是否需要移除感染的起搏器存在争议。